Vis enkel innførsel

dc.contributor.authorLau, Corinna
dc.contributor.authorMcAdam, MB
dc.contributor.authorBergseth, G
dc.contributor.authorGrevys, Algirdas
dc.contributor.authorBruun, JA
dc.contributor.authorLudviksen, Judith K
dc.contributor.authorFure, Hilde
dc.contributor.authorEspevik, Terje
dc.contributor.authorMoen, A
dc.contributor.authorAndersen, Jan Terje
dc.contributor.authorMollnes, Tom Eirik
dc.date.accessioned2020-02-03T13:27:51Z
dc.date.available2020-02-03T13:27:51Z
dc.date.created2020-01-13T16:06:05Z
dc.date.issued2020
dc.identifier.citationmAbs. 2020, 12 (1)nb_NO
dc.identifier.issn1942-0862
dc.identifier.urihttp://hdl.handle.net/11250/2639333
dc.description.abstractThe mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab (Soliris®), which is used clinically to block complement factor C5, as well as anti-human CD14 (r18D11) and anti-porcine CD14 (rMIL2) produced in our laboratory. So far, no proper IgG2/4 control antibody has been available for controlled validation of IgG2/4 antibody functions. Here, we describe the design of a recombinant control antibody (NHDL), which was generated by combining the variable light (VL) and heavy (VH) chains from two unrelated specificities. NHDL was readily expressed and purified as a stable IgG2/4 antibody, and showed no detectable specificity toward any putative antigen present in human or porcine blood. The approach of artificial VL/VH combination may be adopted for the design of other recombinant control antibodies.nb_NO
dc.language.isoengnb_NO
dc.publisherTaylor & Francisnb_NO
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleNHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies.nb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.volume12nb_NO
dc.source.journalmAbsnb_NO
dc.source.issue1nb_NO
dc.identifier.doi10.1080/19420862.2019.1686319
dc.identifier.cristin1771769
dc.description.localcode© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.nb_NO
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal